Close Menu

NEW YORK – Clovis Oncology said on Wednesday that the US Food and Drug Administration accepted its supplemental new drug application of rucaparib (Clovis' Rubraca) as a treatment for BRCA1/2-mutated metastatic castrate-resistant prostate cancer. 

Additionally, the FDA granted priority review status to rucaparib in this setting. 

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.